All In Biotech

Drug Trial Radar · NCT07021430

Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy

Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy: a Pilot Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 22, 2026

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
University of North Carolina, Chapel HillAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jun 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the feasibility, acceptability, and preliminary effectiveness of a focal mass drug administration program for household members of pregnant women to protect against malaria in pregnancy.

Conditions

  • Malaria Prevention

Interventions

  • Dihydroartemisinin PiperaquineDrug

    A single or monthly dose of Dihydroartemisinin Piperaquine based on weight will be taken orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of eligible household members receiving fMDATime frame: Day 1 to study completion, generally 5 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bugoye Level III Health Center

    Kasese, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.